BioFlash: Alnylam soars; Humana snubs Biogen; Merrimack staffer arrested

If you are having trouble viewing this email, click here

Boston BioFlash

Sponsored by

February 9, 2017

​Alnylam shares jump on positive earnings, 2017 outlook

The Cambridge biotech, which has around 525 employees, is developing drugs that use a technology called RNA interference to silence disease-creating genes.


Humana to limit coverage of pricy Biogen drug

Some analysts have said that coverage disputes could slow the launch of the drug and dent the 2017 earnings of Biogen, the largest life science employer headquartered in Massachusetts.


Cambridge company’s experiment hitches a ride on Elon Musk’s next space rocket

The experiment will test the effects of near-zero gravity on the bacteria known as MRSA, a “super bug” that is resistant to antibiotics and can wreak havoc in hospitals.


Merrimack Pharmaceuticals employee arrested, charged with insider trading

The charges against Westford, Massachusetts resident Songjiang Wang were confirmed by a spokeswoman for the U.S. Attorney’s Office in Boston.


Boston Business Journal Science & Tech Newsletters

Max Stendahl

Biotech Reporter


Connect with us

National Technology News

FDA lifts hold on Northwest Bio’s brain cancer immunotherapy trial

Cancel Email Subscription | View as Web Page

You may change your email address, your preferences, or unsubscribe from this email at any time by visiting

If you need other assistance, please let us know or contact: customer service, bizjournals 120 W. Morehead St., Charlotte, North Carolina 28202

The Business Journals | Latest News | Advertise | Contact Info | Subscribe to Print Edition

© 2017 American City Business Journals, Inc. and its licensors. All rights reserved. The material on this may not be reproduced, distributed, transmitted, cached or otherwise used, except with the written permission of bizjournals.